Heffter Research Institute

program-funding - Landmark psilocybin trials for anxiety and depression in cancer patients - undisclosed

Heffter was the principal funder of the parallel NYU and Johns Hopkins psilocybin cancer-distress studies published in 2016 — landmark work in the modern psychedelic renaissance.

program-funding - Psilocybin-assisted therapy for Alcohol Use Disorder RCT (Heffter's largest supported study) - undisclosed

Described as Heffter's largest supported study; published in JAMA Psychiatry (Aug 2022). Follow-on work carried forward at NYU with support from Carey Turnbull's B.More nonprofit.

fellowship - Funding for three psychiatry post-graduate fellowships in psychedelic medicine - $1,000,000

Board member/Treasurer Carey Turnbull organized and raised $1M for Heffter to fund three psychiatry post-graduate fellowships at Johns Hopkins, NYU and Yale.

grant - New Investigator grants to new researchers and graduate students - $800,000

$800K granted to early-career researchers/grad students across the US, Australia, Switzerland, the Netherlands and Iran (a U. Tehran PhD student completing the project in Sweden).

program-funding - First LSD treatment study in ~50 years — chronic back pain in patients who misuse opioids - undisclosed

Heffter funded the first LSD treatment study in roughly 50 years, for chronic back pain patients who misuse opioids at Johns Hopkins.

program-funding - Psilocybin treatment for obsessive-compulsive disorder (OCD) - undisclosed

Among studies Heffter reported supporting in 2022; also seeded Ben Kelmendi's ~$800K NIMH career grant at Yale.

program-funding - Psilocybin treatment for Opioid Use Disorder - undisclosed

Listed among studies Heffter was actively supporting in its 2022 annual report.

program-funding - Psilocybin treatment for depression in hospice patients - undisclosed

Listed among studies Heffter was actively supporting in its 2022 annual report.